ADARx Pharmaceuticals, Inc. (ADRX)
NASDAQ
Closed
Oct 19, 2026
Day's Range
17.0552 wk Range
16.64Profile - ADRX - ADARx Pharmaceuticals, Inc.
Profile
Mic Code
XNMS
Sector
Healthcare
Industry
Biotechnology
Employees
100
ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing next-generation siRNA therapeutics. The company works on RNA interference-based medicines designed to silence disease-causing genes and address conditions with significant unmet medical needs. Its current pipeline includes hepatic-targeted programs such as Agazisiran, a complement factor B program, Onvuzosiran for hereditary angioedema attack prevention, and ADX-626, a Factor XI program being studied for thrombotic disease and stroke prevention applications. ADARx Pharmaceuticals operates in the broader genetic medicine and precision therapeutics markets, where it aims to translate advanced oligonucleotide science into targeted treatments across multiple disease areas. Based in San Diego, California, the company is positioned as a clinical biotechnology developer with a focus on translational research and specialty drug development.
Profile Details
Type
Common Stock
Ceo
Dr. Zhen Li Ph.D.
Address
5871 Oberlin Drive
City
San Diego
State
CA
Zip
92121
Country
United States
Phone
(877) 232-7974
Key Executives - ADRX - ADARx Pharmaceuticals, Inc.
Key executives
Cross Listings - ADRX - ADARx Pharmaceuticals, Inc.
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
